Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Volpara Health Technoligies Ltd (ASX:VHT) Shares Rocketed Today

Volpara Health Technologies Ltd (ASX: VHT) shares soared 21% today, posting the largest percentage gain on the All Ordinaries Index (ASX: XAO).

Volpara Health Technologies Ltd (ASX: VHT) soared 21% today, posting the largest percentage gain on the All Ordinaries Index (ASX: XAO).

What’s a Volpara?

Volpara is yet another gem from New Zealand; think A2 Milk Company Ltd (ASX: A2M) and Xero Limited (ASX: XRO).

Based in Wellington, the company is a medical technology company whose AI algorithms assist in the early detection of breast cancer. The Saas business was founded in 2009 on research originally conducted at Oxford University, and their technology and services have been used by customers and research projects in 37 countries.

Why’s the VHT share price off to the moon?

This morning Volpara announced they had reached their commercial milestone for FY19, which was for 85% growth in Annual Recurring Revenue (ARR) and coverage of 7% of women screened in the United States.

ARR now stands at NZ$6.6 million, compared to NZ$3.6 million at the end of FY18, an increase of 86%.

Other highlights in the announcement included the signing of their first NZ$1 million total contract value customer in the US and the signing of the large I-MED Radiology network in Australia this quarter.

Last month, Volpara announced the launch of an expanded agreement enabling the worldwide distribution of its industry-leading VolparaDensity software by GE Healthcare, a subsidiary of US behemoth General Electric Company (NYSE: GE).

They also announced that the United States Food and Drug Administration (FDA) has released a proposal to amend the Mammography Quality Standards Act to include a requirement that all US screening facilities provide information on breast density to women and their healthcare providers after a mammogram.

Volpara has a 31 March year-end and will announce their full-year result at the end of May.

Buy, Hold or Sell

I think Volpara has a great future and today’s announcement shows the business has strong momentum. However keep in mind that it has a $300 million market capitalisation, so it’s a smaller company and the shares will likely be a lot more volatile than the general share market.

If you’re on the lookout for the next Volpara, get a free copy of our ASX investing report below…

[ls_content_block id=”18457″ para=”paragraphs”]

Disclosure : At the time of writing David owns Volpara shares.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content